Upstream Bio, Inc. (UPB): Depreciation & Amortization
$188.0K
Year ended 2025-12-31
$202.0K
Trailing 12 months to 2026-06-30
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $188.0K | +111.2% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $89.0K | +48.3% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $60.0K | n/a | 2025-03-12, From 2023-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $188.0K | +111.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $384.0K | -24.6% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $68.8K | -27.9% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $1.64M | -3.4% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $60.8K | +47.9% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $1.50M | -42.6% |
| Bio Essence Corp (BIOE) | 2025-12-31 | $235 | -74.2% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $4.83M | -21.9% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $900.0K | -12.5% |
Compare UPB, TXMD, GOVX, CAMP side by side · Screen every company in Pharmaceutical Preparations ↗